Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
March 13, 2023: Biosergen today announced completion of the phase 1 study with BSG005. The study included both a single ascending dose (SAD) and a multiple ascending dose (MAD) part. Topline data showed a satisfactory safety profile with no serious adverse events reported and no impact on kidney and liver function after BSG005 administration both as single infusions as well as after 7-days repeated IV infusions at multiple dose levels. The repeated IV infusion treatment regimen and the satisfactory safety profile supports advancement of testing BSG005 in a phase 2 clinical study in